Clinical effects of antiplatelet drugs and statins on D-dimer levels by Schol-Gelok, S. et al.
OR I G I N A L AR T I C L E
Clinical effects of antiplatelet drugs and statins on D-dimer
levels
Suzanne Schol-Gelok1 | Tom van der Hulle2 | Joseph S. Biedermann3 |
Teun van Gelder1 | Frederikus A. Klok2 | Liselotte M. van der Pol2 |
Jorie Versmissen1 | Menno V. Huisman2 | Marieke J. H. A. Kruip3
1Department of Hospital pharmacy and
Internal Medicine, Erasmus University
Medical Center, Rotterdam, The
Netherlands
2Department of Thrombosis and
Haemostasis, Leiden University Medical
Center, Leiden, The Netherlands
3Department of Hematology, Erasmus
University Medical Center, Rotterdam,
The Netherlands
Correspondence
Suzanne Schol-Gelok, Department of
Hospital pharmacy and Internal Medicine,
Erasmus University Medical Center
Rotterdam, Rotterdam, The Netherlands.
Email: s.schol-gelok@erasmusmc.nl
Funding information
Dutch Society for Clinical Pharmacology
& Biopharmacy
Abstract
Background: Acute pulmonary embolism may be ruled out by combining non-
high clinical probability and a normal D-dimer level. Both antiplatelet drugs and
HMG-CoA reductase inhibitors (statins) have been associated with effects on
thrombus formation, potentially influencing D-dimer levels in this setting, leading
to a higher rate of false-negative tests. Therefore, we determined whether D-dimer
levels in patients with suspected pulmonary embolism are affected by concomitant
use of antiplatelet drugs and/or statins and evaluated whether the effect of antipla-
telet drugs or statins might affect diagnostic accuracy.
Materials and methods: We performed a posthoc analysis in the YEARS diag-
nostic study, comparing age- and sex-adjusted D-dimer levels among users of
antiplatelet drugs, statins and nonusers. We then reclassified patients within the
YEARS algorithm by developing a model in which we adjusted D-dimer cut-offs
for statin use and evaluated diagnostic accuracy.
Results: We included 156 statins users, 147 antiplatelet drugs users and 726
nonusers of either drugs, all with suspected pulmonary embolism. Use of antipla-
telet drugs did not have a significant effect, whereas statin use was associated
with 15% decrease in D-dimer levels (95% CI, 28% to 0.6%). An algorithm
with lower D-dimer thresholds in statin users yielded lower specificity (0.42 com-
pared to 0.33) with no difference in false-negative tests.
Conclusions: We conclude that use of statins but not of antiplatelet agents is
associated with a modest decrease in D-dimer levels. Adjusting D-dimer cut-offs
for statin use did, however, not result in a safer diagnostic strategy in our cohort.
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1 | INTRODUCTION
D-dimer levels have a central role in the diagnostic work-
up of venous thromboembolism (VTE). Guidelines recom-
mend combining clinical decision rules and a D-dimer test
to identify patients in whom pulmonary embolism (PE) or
deep venous thrombosis may be ruled out without perform-
ing imaging tests (high level of evidence).1,2 Recently, the
YEARS algorithm, incorporating a variable D-dimer cut-off
dependent on the pretest probability based on 3 clinical
variables (Figure 1), has been proven to be safe and com-
patible with clinical practice.3
D-dimers are fibrin degradation fragments, generated
after fibrinolysis of a blood clot by the sequential action of
thrombin, factor XIIIa and plasmin.4 The D-dimer level in
blood can be influenced by many factors such as age,
active malignancy, infection, pregnancy or use of anticoag-
ulants.5-8 Other drugs that affect thrombus formation and
therefore may influence D-dimer levels as well are antipla-
telet drugs and HMG-CoA reductase inhibitors, more com-
monly known as statins. Antiplatelet drugs can delay
thrombin generation and in general inhibit blood coagula-
tion.9 Statins inhibit a variety of platelet factors and
decrease tissue factor activity.10,11 Through the latter mech-
anism, a smaller amount of factor X is activated and gener-
ation of thrombin is depleted. These effects might explain
that statins may exert cardiovascular protective effects that
are independent of LDL-cholesterol lowering, the so-called
pleiotropic effects.12 Indeed, most clinical studies on this
subject have found that statin therapy, especially treatment
with lipophilic statins (simvastatin, atorvastatin or fluvas-
tatin), does lower D-dimer levels whereas antiplatelet ther-
apy does not seem to have an effect. 13 Although most
studies are retrospective and susceptible to bias due to
other factors influencing D-dimer level.13-19 Studies on the
effect of statins and antiplatelet therapy on the sensitivity
of D-dimer used as diagnostic test in patients with sus-
pected PE are lacking.
To test the hypothesis that D-dimer cut-offs may need
to be adjusted in statin and/or antiplatelet therapy users, we
performed a posthoc analysis of the YEARS diagnostic
study.3 D-dimer levels were compared among users and
nonusers of antiplatelet drug and/or statin. Further, we
evaluated the rate of false-negative D-dimer tests among
users of statins, as well as the sensitivity and specificity of
D-dimer thresholds adjusted to statin use.
2 | METHODS
2.1 | Study design
This was a posthoc analysis within the YEARS study, of
which the design was previously described in detail
(Netherlands Trial Registry number NTR4193).3 Briefly,
3465 patients with suspected acute PE were included
between 5 October 2013 and 9 July 2015 in a prospective
multicentre cohort outcome study evaluating the safety and
accuracy of the YEARS diagnostic algorithm. In this algo-
rithm, patients were managed by combining simultaneous
assessment of a clinical decision rule consisting of 3 items
(clinical signs of deep vein thrombosis (DVT), haemopty-
sis, PE most likely diagnosis) and a D-dimer test. In
patients without YEARS items and D-dimer <1000 ng/mL,
or ≥1 YEARS items and D-dimer <500 ng/mL, PE was
considered excluded without further imaging. All other
patients underwent computed-tomography pulmonary-
angiography (CTPA; Figure 1).
D-dimer levels were measured upon presentation of the
patient, using automated high-sensitive quantitative D-
dimer assays (according to local practice Vidas D-dimer
Exclusion; Biomerieux, Marcy-L’Etoile, France; STA-
LIA; DiagnosticaStago, Asnieres, France; Innovance;
FIGURE 1 YEARS algorithm¹. CTPA, computed-tomography pulmonary angiography; DVT, deep vein thrombosis; PE, pulmonary
embolism; ¹ Figure derived with permission of publisher from: van der Hulle T, Cheung WY, Kooij S, et al Simplified diagnostic management
of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet 2017;390(10091):289-297
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Siemens, Marburg, Germany). At study inclusion, the fol-
lowing baseline characteristics were assessed: age, sex,
body mass index (BMI), smoking status, malignancy,
hypertension, CRP level, previous VTE and present use of
antiplatelet drugs and statins.
Follow-up consisted of a scheduled outpatient visit or
telephone interview after 3 months. At this visit, informa-
tion was obtained on complaints suggestive of VTE. In
case of clinically suspected VTE during follow-up, objec-
tive diagnostic tests were required, including CTPA for
suspected PE and compression ultrasonography for sus-
pected deep vein thrombosis.
2.2 | Patients
Hospitalized patients as well as patient visiting the emer-
gency department with clinically suspected acute (first or
recurrent) PE were eligible for inclusion in the YEARS
study if they were 18 years of age or older. Exclusion cri-
teria were as follows: treatment with therapeutic doses of
anticoagulants initiated ≥24 hours prior to eligibility assess-
ment, life expectancy less than 3 months, geographic inac-
cessibility precluding follow-up, pregnancy or allergy to
intravenous contrast agent. In two of the participating hos-
pitals—the Erasmus University Medical Center and the
Leiden University Medical Center—we also obtained data
about use of antiplatelet drugs and statins. For that reason,
we restricted the present posthoc analysis to patients evalu-
ated in the latter 2 hospitals.
2.3 | Study aim and endpoints
The primary aim of this study was to assess the effect of
antiplatelet drugs and statins on D-dimer levels in patients
suspected of PE. The secondary aim of this study was to
evaluate whether the effect of antiplatelet drugs or statins
might affect diagnostic accuracy.
The primary endpoint of this study was the difference
in D-dimer levels among users and nonusers of antiplatelet
drugs and statins. The secondary endpoints of this study
were the proportion of patients categorized differently in
the YEARS algorithm and the change in diagnostic accu-
racy and diagnostic failure rate (VTE related death, VTE or
lost to follow-up) when the effect of statins on D-dimer
levels is taken into account. Reporting of this study con-
forms to the STROBE statement and the broader EQUA-
TOR guidelines.20
2.4 | Statistical analysis
D-dimer levels were log-transformed to normalize the dis-
tribution. Multiple linear regression analyses were per-
formed with adjustment for age, sex, current smoking, use
of antiplatelet drugs, use of statins, current smoking and
history of VTE according to different stepwise regression
models. The contribution of these variables to the changes
in D-dimer levels was determined by comparing the
explained variance from the different multivariable linear
regression analyses. Due to missing data in 397 (43%)
patients, we could not adjust for BMI. The variables that
explained most of the change in D-dimer were then identi-
fied. We calculated change in D-dimer levels for each drug
exposure by exponentiation of the correlation coefficient
and their corresponding 95% confidence intervals (95%
CI). A two-sided P-value of .05 was considered to indicate
statistical significance. All statistical analyses were carried
out using “IBM SPSS Statistics for Windows, version 21
(IBM Corp., Armonk, N.Y., USA).”
For the secondary outcome analysis, we tested the
amount of patients that should have been managed differ-
ently in the YEARS algorithm when the effect of antiplate-
let drugs and/or statins on D-dimer levels was taken into
account. Therefore, we developed a model to reclassify
antiplatelet drugs and/or statin users by adjusting the D-
dimer cut-offs. The cut-offs were adjusted based on the
expected change in D-dimer levels, as derived from the
regression analysis, and were inserted posthoc in the
YEARS algorithm. Further, we evaluated diagnostic accu-
racy by comparing the diagnostic failure rate (VTE related
death, VTE or lost to follow-up) with and without this
reclassification of antiplatelet drugs and/or statin users in
the YEARS algorithm.
3 | RESULTS
Within the YEARS study, 925 patients were included in
this posthoc analysis. Mean age of these patients was
54 years (standard deviation (SD) 17), and mean BMI was
27 kg/m2 (SD 5.7); 369 of them (39.9%) were male, and
178 (19.2%) current smokers. Following the YEARS algo-
rithm, 395 (42.7%) patients scored no YEARS items, 479
(51.8%) scored 1, 48 (5.2%) scored 2, and 3 (0.3%) patients
scored 3 items. PE was diagnosed by CTPA at baseline in
16.1% of the patients not using an antiplatelet drug or a
statin, compared to 17.1% of the patients using either drug.
Among the group of patients in whom PE was excluded
using the YEARS algorithm, only 2 developed a PE during
follow-up and in 1 patient, PE could not be excluded as
cause of death. None of these patients used antiplatelet
drugs or statins. In total, 5 patients were lost to follow-up
and four of them did not use either drug.
The mean D-dimer level was 1666 ng/mL (SD
1642 ng/mL) and the median 985 ng/mL (interquartile
range 479-1203 ng/mL). Of all patients, 22% used an anti-
platelet agent and/or statin. More than half of them
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(n = 104) were using both drugs, 43 patients were only
using antiplatelet drugs and 52 patients only statins. In
72% of the statin users, a lipophilic statin (simvastatin,
atorvastatin or fluvastatin) had been prescribed. Median D-
dimer values were 912 ng/mL (interquartile range 573-
1941 ng/mL) in lipophilic statin users compared to
1050 ng/mL (558-1540 ng/mL) in hydrophilic statin (rosu-
vastatin and pravastatin) users, but this difference was non-
significant. Compared to nonusers, antiplatelet drug and/or
statin users were older, had a higher BMI, smoked less,
and the proportion of male gender, previous VTE and the
presence of hypertension was higher (Table 1). There was
no difference in the median level of CRP or the presence
of malignancy between users and nonusers of antiplatelet
drug and/or statins.
3.1 | The effect of antiplatelet drugs and
statins on D-dimer levels
We estimated the proportion of the variation (R² value) and
change in plasma D-dimer levels explained by age, sex,
current smoking, use of antiplatelet drugs, use of statins,
history of VTE in different linear regression models
(Table 2). The change in plasma levels of D-dimer was
explained for 18.3% by age, sex, use of antiplatelet drugs
and use of statins. Notably, age explained most of the
proportion of variation (17.8%) and current smoking added
a significant 0.8% of the explained variance to this model.
When adjusted for age, sex and use of statins, use of
antiplatelet drugs resulted in a decrease of 7.6% (95% CI,
25% to 13%). In this similar regression model, use of sta-
tins resulted in a 12% (95% CI, 27% to 7.5%) decrease of
D-dimer values. Both these correlations were not signifi-
cant. Yet, when only adjusted for age and sex, use of sta-
tins was significantly correlated and was associated with a
reduction of D-dimer values by 15% (95% CI, 28% to
0.6%). A subgroup regression analysis with inclusion of
only lipophilic statin users and nonstatin users and adjust-
ment for age and sex did not result in a significant correla-
tion (12.5% decrease, 95% CI, 27% to 5%).
3.2 | Model for reclassifying statin users
within the YEARS algorithm
As antiplatelet drugs did not show any significant effect on
D-dimers, we only calculated adjusted D-dimer cut-offs for
statin users. This calculation was based on the results of
the linear regression model containing age, sex and use of
statins. Adhering to this model, we adjusted the D-dimer
cut-off to be 15% lower for patients using statins. This
resulted in an adjusted cut-off determined at 850 ng/mL
instead of 1000 ng/mL for patients having no YEARS
TABLE 1 General characteristics of patients






drugs (n = 43)
Statins and
antiplatelet
drugs (n = 104)
Statins and/or
antiplatelet drugsa,b
(n = 199) P-value*
Male (%) 271 (37.3) 21 (40.4) 21 (48.8) 56 (53.8) 98 (49.2) .002
Age 48.7 (17.2) 61.7 (12.0) 69.6 (14.7) 67.5 (11.9) 66.4 (12.9) <.001
Body mass index (kg m¯²) 26.0 (5.4) 30.1 (6.5) 26.5 (5.9) 28.8 (5.6) 28.6 (6.0) <.001
CRP (mg/L) 9 (3-32) 10 (3-26) 7 (3-29) 7 (3-19) 7 (3-22) .89
Hypertension 108 (14.9) 33 (63.5) 19 (45.2) 67 (65.0) 119 (60.4) <.001
Current smoker 154 (21.9) 6 (11.8) 6 (14.0) 12 (11.7) 24 (12.2) .003
Prior VTE 71 (9.8) 11 (21.2) 8 (18.6) 11 (10.6) 30 (15.1) .03
Malignancy 104 (14.3) 6 (11.5) 8 (18.6) 11 (10.6) 25 (12.6) .52
PE at CTPA 117 (16.1) 13 (25.0) 10 (23.3) 11 (10.6) 34 (17.1) .45
Death of any reason
during follow-up
44 (6.1) 1 (1.9) 2 (4.7) 2 (1.9) 5 (2.5) NA
PE during follow-up 2 (0.3) 0 (0) 0 (0) 0 (0) 0 (0) NA
Lost to follow-up 1 (0.1) 0 (0) 0 (0) 0 (0) 1 (0.5) NA
CTPA, computed-tomography pulmonary-angiography; PE, pulmonary embolism; VTE, venous thromboembolism. Data are shown as mean values (SD); numbers
(percentages) or median (interquartile ranges). Due to missing data, n = 529 for body mass index; n = 897 for CRP; n = 920 for hypertension; n = 901 for smoking;
n = 924 for prior VTE; n = 924 for malignancy.
aantiplatelet drugs: acetylsalicylic acid n = 136; clopidogrel n = 6; other n = 3; unknown n = 2;
bstatins: simvastatin n = 73; rosuvastatin n = 22; atorvastatin n = 36; pravastatin n = 19; fluvastatin n = 3; unknown n = 3.
*P-value between groups no use vs use of statins and/or antiplatelet drugs; Pearson chi-square test for categorical variables; Mann Whitney U test for continuous
variables.
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criteria. For patients having 1 or more YEARS criteria, the
adjusted cut-off was determined at 425 ng/mL instead of
500 ng/mL.
3.3 | Performance of YEARS algorithm after
reclassification of statin users
In the original YEARS algorithm, we found that 56 statin
users (35.9%) were managed without CTPA. None of
these patients was lost to follow-up, no VTE or VTE-
related death was detected. When we tested the algorithm
using the adjusted cut-offs, thus incorporating the effects
of statins on D-dimer levels, we found that 12 patients
were reclassified to the group needing a CTPA to rule
out PE. In these patients, we did not detect any additional
diagnostic failures during follow-up, in 1 patient, CTPA
was conducted for other reasons, showing no PE
(Table 3). After reclassification of these 12 patients, speci-
ficity decreased from 0.42-0.33, while sensitivity did not
change.
4 | DISCUSSION
Our study results showed that in our population of
patients suspected of having a PE, statins decreased D-
dimer levels but antiplatelet drugs did not. Adjusting D-
dimer cut-offs for statin use did, however, not result in
a safer diagnostic strategy. Based on our study, there is
no need for adjusting D-dimer cut-off values for statin
users. Moreover, age explained the largest proportion of
the D-dimer variance, underlining that age has a higher
impact on D-dimer levels than antiplatelet drugs and
statins.
Nowadays, diagnostic algorithms for detecting PE are
sensitive, but overall 3-month diagnostic failure rate is still
not reduced to zero.21-23 This is, to our best knowledge,
the first study to test the effect of statins and antiplatelet
drugs on the sensitivity of D-dimer tests for the diagnosis
of acute VTE. The reported effect of statins on D-dimer
levels differs between previous studies. Both the results of
a review and a meta-analysis suggested a decrease in
plasma D-dimer levels with the use of statins.13,15 One
small intervention study in patients with hypercholestero-
laemia for example did not show a significant change in
D-dimer levels after start of treatment with statins whereas
another study including type 2 diabetes patients found a
significant reduction of approximately 8% in D-dimer
levels.18,24 The studies included in this review and meta-
analysis concerned different patient populations, not taking
into account concurrent antiplatelet therapy.25,26 This is dis-
similar to our study, in which we analysed the effect of
antiplatelet drugs and statins separately. Our study results
are best compared with those of a study by Adams et al14
comparing haemostatic factor levels between statin users
and nonusers. In a cohort of 6814 healthy men and women
age 45-84 years, participants using statins had a 9% lower
D-dimer level after adjusting for age, race/ethnicity, educa-
tion, income, hormone replacement therapy and major car-
diovascular risk factors. The main difference with our
study is that this was a cohort study in a healthy popula-
tion, whereas in our study, D-dimers levels were deter-
mined in the clinical setting of suspected PE. Another
difference is that we could not adjust for all cardiovascular
risk factors (including BMI and diabetes status), race/eth-
nicity, education, income and hormone replacement ther-
apy, as these data were not fully collected at baseline.
Notably, in our subgroup analysis with inclusion of only
TABLE 2 Effect on D-dimers according to the different linear regression models






in users for statins
(95% CI)**
Adjusted % change in
D-dimer for antiplatelet
drug users (95% CI)**
Age 17.8 Not applicable Not applicable
Age and use of statins 18.2 15% (28%; 1.4%)*** Not applicable
Age, sex, use of statins 18.2 15% (28%; 0.6%)*** Not applicable
Age, sex, use of lipophilic statins 18.6 12.5% (27%; 5%) Not applicable
Age, sex, use of statins, use of antiplatelet drugs 18.3 12% (27%; 7.5%) 7.6% (25%;13%)
Age, sex, use of statins, use of antiplatelet drugs,
current smoker
19.1 11% (27%; 8.0%) 7.6% (25%;13%)
Age, sex, use of statins, use of antiplatelet drugs,
current smoker, history of VTE
19.3 11% (27%; 7.6%) 7.0% (24%;14%)
*R² value.
**adjusted change in D-dimer values calculated by exponentiation of the correlation coefficient and their corresponding 95% confidence intervals (95% CI).
***significant P-value < .05.
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lipophilic statin users and nonusers of statins, we could not
detect a significant correlation with D-dimer levels, how-
ever, we might have been underpowered.
The evidence for the absence of effect of antiplatelet
drugs on D-dimers is compellingly illustrated in 2 studies
in healthy male volunteers using acetylsalicylic acid.16,27
One of these studies was a randomized placebo controlled
trial in 30 healthy volunteers. Also, Kamath et al17 showed
that D-dimer levels in patients with atrial fibrillation treated
with aspirin were not lower than in those given no treat-
ment. A study in patients on peritoneal dialysis likewise
found no effect on D-dimer levels in those using low-dose
aspirin for 8 weeks.28
A methodological strength of this posthoc analysis in
the YEARS population is that we studied a real-world
cohort of patients with a near complete follow-up. Also,
using the different linear regression models, the change in
proportion of the variation explained by each variable and
in particular statins could be extracted. Having analysed
this population in daily practice using a clinical approach,
we expect that results can be easily interpreted and trans-
lated to clinical care.
Limitations of our study include that this reports on a
posthoc finding of a large outcome study, in which
extensive data on baseline medication use were only
available for two of the participating centres. For this
reason, the secondary endpoints of our study are likely
underpowered and we cannot rule out a relevant effect
of statin use in clinical practice with sufficient certainty.
Nevertheless, our study offers currently the best available
evidence evaluating the diagnostic accuracy of a clinical
diagnostic algorithm on PE in statin users explicitly.
Also, we expect that a separate prospective study
designed and powered to address these endpoints specifi-
cally will probably not be performed in future because
of lack of financial incentives. Another limitation of our
study is that CTPA results of the reclassified statin users
were not available and the change in D-dimer in statin
users was used for modification of the D-dimer cut-off
in the same population. Also, the adjusted cut-offs were
calculated posthoc and management decisions were based
on the original cut-offs. Therefore, extrapolation of our
findings to other populations or healthcare settings war-
rants caution. Further, we used different quantitative D-
dimer assays and were unable to stratify the results by
assay, as patient-level information on the assay used was
not available. However, all were contemporary, well-vali-
dated high-sensitive quantitative D-dimer assays with
similar fixed cut-off levels.29
Based on our results, we conclude that use of statins is
associated with a 15% decrease in D-dimer levels. In our
cohort, this was not associated with an increase in false-
negative test results, compared to nonusers. Nevertheless,
further validation in a larger clinical cohort would be
needed, however, we consider it unlikely that a prospective
study designed and powered to address all endpoints sepa-
rately will be performed in future.
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Death during follow-up or
lost to follow-up (yes/no)
1 M 79 1 442 Yes No No
2 F 70 1 450 No No No
3 M 76 1 468 Yes No No
4 M 62 1 470 Yes No No
5 M 72 1 480 No No No
6 M 62 1 492 No No No
7 M 67 0 860 Yes No No
8 F 54 0 890 No No No
9 M 77 0 910 Yes No No
10 F 74 0 913 No No No
11 M 85 0 930 Yes No No
12 M 75 0 990 Yes Nob No
Reclassification of statin users having no YEARS and D-dimer ≥ 850 and <1000 ng/mL or statin users having YEARS ≥ 1 and D-dimer ≥ 425 and <500 ng/mL.
aDiagnostic failures are defined by venous thromboembolism during follow-up, VTE-related death during follow-up or lost to follow-up.
bCTPA (computed-tomography pulmonary-angiography) conducted during follow-up showing no pulmonary embolism.
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